Scott M. Davies
Known title: Interim General CounselCIK: 0002040663
Associated companies
Transaction History
| ILMN | ▼ Sell | Open Market | 615 | $123K | 7/30/2026 | View on chart |
| ILMN | ▼ Sell | Open Market | 615 | $111K | 6/25/2026 | View on chart |
| ILMN | ▼ Sell | Open Market | 615 | $98K | 5/29/2026 | View on chart |
| ILMN | ▲ Buy | Grant | 5,849 | $750K | 3/5/2026 | View on chart |
| ILMN | ▼ Sell | Open Market | 1,336 | $155K | 2/20/2026 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,037 | $121K | 2/15/2026 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 550 | $63K | 2/12/2026 | View on chart |
| ILMN | ▲ Buy | Option Exercise | 1,370 | $0 | 2/12/2026 | View on chart |
| ILMN | ▼ Sell | Open Market | 323 | $44K | 12/12/2025 | View on chart |
| ILMN | ▼ Sell | Other | 323 | $40K | 11/12/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 398 | $49K | 11/5/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 7,002 | $0 | 3/5/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 407 | $41K | 2/15/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,068 | $148K | 1/5/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 474 | $73K | 11/5/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.